Acuity Medical

Macular degeneration device improves vision in 26% of treated eyes in trial

Published in Biotech Law Weekly, November 11th, 2005

Acuity Medical has successfully completed a proof of concept U.S. Food and Drug Administration-compliant trial of its TheraMac device for the treatment of dry age-related macular degeneration (AMD).

AMD is the leading cause of legal blindness effecting more than 50 million people worldwide. The trial showed that in 2 weeks 26% of the eyes treated had improved vision by 10 letters or more, the equivalent of two lines on the eye chart. There were zero serious adverse events.

TheraMac produces minute amounts of electrical biocurrent that is delivered to the retina through a probe touching the skin around the eye. The biocurrent facilitates increases in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2005-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry